Your session is about to expire
← Back to Search
Neuromuscular Blocking Agent
BX1000 0.15 mg/kg for Neuromuscular Blockade
Phase 2
Waitlist Available
Research Sponsored by Baudax Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 2 minutes after administration
Awards & highlights
Study Summary
This trial studies effects of two drugs on conditions during intubation: BX1000 (experimental) and rocuronium (standard).
Eligible Conditions
- Neuromuscular Blockade
- Anesthesia
- Surgery
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within 2 minutes after administration
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 2 minutes after administration
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assessment of Intubation Conditions
Secondary outcome measures
Assessment of Neuromuscular Recovery
Assessment of Onset of Neuromuscular Blockade
Assessment of Safety And Tolerability - Adverse Events
+3 moreTrial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: BX1000 0.35 mg/kgExperimental Treatment1 Intervention
BX1000 0.35 mg/kg IV Bolus
Group II: BX1000 0.25 mg/kgExperimental Treatment1 Intervention
BX1000 0.25 mg/kg IV Bolus
Group III: BX1000 0.15 mg/kgExperimental Treatment1 Intervention
BX1000 0.15 mg/kg IV Bolus
Group IV: Rocuronium 0.6 mg/kgActive Control1 Intervention
Rocuronium bromide 0.6 mg/kg IV Bolus
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BX1000
2022
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
Baudax BioLead Sponsor
10 Previous Clinical Trials
1,779 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger